Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Difenpiramide is a non-steroidal anti-inflammatory drug (NSAID) belonging to the acetic acid derivatives class. It is a monocarboxylic acid amide formed by the condensation of biphenyl-4-ylacetic acid and 2-aminopyridine. Difenpiramide has been used primarily for the treatment of musculoskeletal and joint disorders, including rheumatoid arthritis and osteoarthritis. Its pharmacological actions include anti-inflammatory, analgesic (non-narcotic), antipyretic, and uricosuric effects. The drug acts mainly by inhibiting cyclooxygenase (COX), thereby blocking prostaglandin synthesis involved in inflammation, pain, and fever. Unlike many NSAIDs, difenpiramide does not significantly affect platelet aggregation or blood clotting. Clinical studies have shown it to be effective with a favorable safety profile; gastrointestinal side effects are rare and generally mild[1][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on difenpiramide.